Common adverse reactions in controlled clinical trials

In RA studies, adverse reactions reported by ≥3% of patients treated with CIMZIA dosed every other week during placebo-controlled period with concomitant methotrexate (MTX)1

  CIMZIA 200 mg EOW + MTX (%) (n=640) Placebo + MTX (%) (n=324)
UPPER RESPIRATORY TRACT INFECTION 6 2
HEADACHE 5 4
HYPERTENSION 5 2
NASOPHARYNGITIS 5 1
BACK PAIN 4 1
PYREXIA 3 2
PHARYNGITIS 3 1
RASH 3 1
ACUTE BRONCHITIS 3 1
FATIGUE 3 2
  • Less than 2% of CIMZIA patients reported injection site pain in clinical trials2

In controlled CD clinical studies, the most common adverse reactions (≥5% of CIMZIA-treated patients and with a higher incidence compared to placebo)1

  CIMZIA (n=620) Placebo (n=614)
UPPER RESPIRATORY TRACT INFECTION 20% 13%
URINARY TRACT INFECTION 7% 6%
ARTHRALGIA 6% 4%
See Warnings and Precautions, including Boxed Warning, regarding tuberculosis, malignancies, and lymphoma
  • Less than 2% of CIMZIA patients reported injection site burning or stinging in clinical trials2